Moxifloxacina Hikma (Moxifloxacin)

Moxifloxacina Hikma is a fluoroquinolone antibiotic used to treat infections caused by susceptible bacteria.

• Community‑acquired bacterial pneumonia: achieves rapid bacterial clearance and clinical improvement.
• Acute bacterial sinusitis: reduces sinus inflammation and resolves infection.
• Acute bacterial exacerbation of chronic bronchitis: improves airflow and decreases bacterial load.
• Skin and skin structure infections: eradicates pathogenic organisms in soft‑tissue infections.
• Intra‑abdominal infections: provides broad‑spectrum coverage for mixed aerobic and anaerobic pathogens.

• Moxifloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. By binding to these targets, the drug prevents the supercoiling and separation of bacterial DNA, leading to bactericidal activity against a wide range of Gram‑positive and Gram‑negative organisms.

Moxifloxacina Hikma may cause adverse reactions that vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: may be watery or loose.
• Headache: transient and often resolves without intervention.
• Dizziness: occasional light‑headed sensation.
• Rash: mild skin erythema or pruritus.
• Elevated liver enzymes: transient increase in hepatic transaminases.

Serious or Rare Side Effects

• Tendon rupture: especially Achilles tendon, may occur without warning.
• QT interval prolongation: risk of cardiac arrhythmias.
• Severe allergic reactions: anaphylaxis, angioedema, or bronchospasm.
• Clostridioides difficile‑associated diarrhea: potentially life‑threatening colitis.
• Hepatic failure: rare but may present with jaundice and elevated bilirubin.
• Stevens‑Johnson syndrome/toxic epidermal necrolysis: severe mucocutaneous reactions.

Before initiating therapy with Moxifloxacina Hikma, consider the following precautions.

• Renal impairment: monitor renal function and adjust therapy as needed.
• History of tendon disorders: avoid use in patients with prior tendon injury.
• QT prolongation risk: obtain baseline ECG and avoid concurrent QT‑prolonging drugs.
• Concurrent antacids containing aluminum or magnesium: separate administration by at least 2 hours.
• Pregnancy and lactation: use only if potential benefits justify the risks.
• Store at 2‑8°C: keep refrigerated, protect from light, do not freeze.

Moxifloxacina Hikma can interact with several medicines, requiring careful management.

Major Interactions (Avoid)

• Antacids with aluminum or magnesium: reduce absorption; separate dosing.
• Warfarin: may increase INR and bleeding risk.
• QT‑prolonging agents (e.g., quinidine, amiodarone): heighten arrhythmia risk.
• Systemic corticosteroids: increase tendon rupture potential.
• Theophylline: may raise plasma theophylline concentrations.

Moderate Interactions (Monitor Closely)

• NSAIDs: may enhance central nervous system toxicity.
• Oral contraceptives: possible reduction in contraceptive efficacy.
• Cyclosporine: may increase cyclosporine levels.
• Insulin or oral hypoglycemics: risk of hypoglycemia.
• Digoxin: potential for elevated digoxin concentrations.